• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Typhoid vaccine Phase 3 trial in Nepal

byNiki WintersandDeepti Shroff Karhade
January 1, 2020
in Infectious Disease, Pediatrics, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In Nepal, the typhoid conjugate vaccine has proven to be very effective in protecting against typhoid fever.

2. The typhoid antibody titers more than quadrupled in the participants that received the typhoid conjugate vaccine.

Evidence Rating Level: 1 (Excellent)      

Study Rundown: Typhoid fever is a bacterial infection caused by Salmonella that leads to a high fever, weakness, stomach pain, and rash. It is a major public health problem in the summer months among children in South Asian countries, such as India, Bangladesh, Pakistan, and Nepal. The oral vaccine has proven to be less effective in children than adults for multiple reasons. This randomized controlled trial was phase 3 of the typhoid conjugate vaccine to determine efficacy in Nepal, a typhoid fever endemic area. Children in this study received either the typhoid vaccine or control vaccine and were followed for 6 months. In participants who received the typhoid vaccine, typhoid fever occurred less commonly, and antibody titers were higher than the control group. Within a week of vaccination, the most common side effects were pain at the injection site, fever, vomiting, and diarrhea. The typhoid vaccine group reported less adverse events within 1 month and 6 months of the vaccine, when compared to the control group. No deaths related to the vaccine were reported.

Follow-up of these participants is on-going and is important to determine long-term efficacy and safety of the vaccine. If this vaccine proves to be effective long-term, it will be able to help prevent typhoid fever among children and travelers to high-risk countries.

Click to read the study in NEJM

Relevant Reading: The Severe Typhoid Fever in Africa Program Highlights the Need for Broad Deployment of Typhoid Conjugate Vaccines

RELATED REPORTS

Higher SARS-CoV-2 antibody titers in patients hospitalized with MIS-C

#VisualAbstract: Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal

In-Depth [randomized controlled trial]: This phase 3, double-blind, randomized controlled trial included 20,019 participants from Nepal to examine the effectiveness of the typhoid conjugate vaccine in an endemic area. Participants received the vaccine between 2017 and 2018, with follow-up into 2019. Children between the ages of 9 months and 16 years in good health were included in the study. Children were randomly assigned to groups based on age – either the conjugated typhoid vaccine group or meningococcal conjugate vaccine (control). Participants were followed to determine if the vaccine prevented typhoid fever, developed immunogenicity, and reported adverse events. Confirmed typhoid fever occurred in 0.07% of the typhoid vaccine group, compared to 0.38% of the control group. The protective efficacy of the typhoid vaccine was 81.6% (95% CI, 58.8 to 91.8; P<0.001). Vaccine efficacy was 85.1% in participants who had at least 3 days of fever (95% CI; 49.7 to 95.6). 28 days after receiving the vaccine, antibody titers more than quadrupled in 99.1% of the typhoid vaccine group versus 2.1% in the control group. Within 7 days of vaccination, the most common side effects were pain at vaccination site, feeling generally unwell, having a fever, vomiting and diarrhea, and decreased appetite. Within 28 days of the vaccination, 7 adverse events were reported in the typhoid vaccine group versus 10 in the control group. Within 6 months of the vaccination, 61 adverse events were reported in the typhoid vaccine group versus 71 in the control group. The most common adverse events reported were pneumonia and pyrexia.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: antibody titersNepalSouth asiatyphoid vaccine
Previous Post

Association of prehospital plasma transfusion with survival in trauma patients with hemorrhagic shock when transport times are longer than 20 minutes

Next Post

Ultra-processed foods linked to increased risk of type 2 diabetes

RelatedReports

Initial data on the viability of SARS-CoV-2 in aerosol and on surfaces
Chronic Disease

Higher SARS-CoV-2 antibody titers in patients hospitalized with MIS-C

November 17, 2020
#VisualAbstract: Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal
StudyGraphics

#VisualAbstract: Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal

January 16, 2020
Next Post
Dietary variety linked to greater increase in childhood BMI

Ultra-processed foods linked to increased risk of type 2 diabetes

#VisualAbstract: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent

#VisualAbstract: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent

Placebo formulation impacts effectiveness of pain control in osteoarthritis

MIV-711 effective in reducing bone and cartilage manifestations for patients with osteoarthritis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Efanesoctocog alfa is efficacious in treating severe hemophilia A
  • Mavacamten associated with improvement in submaximal exertional tolerance: A secondary analysis of the EXPLORER-HCM randomized trial
  • Sodium-glucose cotransporter 2 inhibitors may reduce incidence of obstructive airway disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options